In multi-marker signature development the goal is that each patient is treated based on his or her specific needs. The choice of treatment and medication can be based on a wide range of factors, increasingly of genomic and proteomic origin. Multi-marker signature development and the associated area of companion diagnostics area are also very relevant in new drug development. When selecting patients that will most likely respond to drugs in clinical trials, genomic and proteomic biomarker data are very often considered.
Intomics track record:
We have successfully worked with clients on development of genomic and expression-based signature for patient stratification, based on pre-clinical and clinical phase data. Across these projects we have shown the ability to identify responding patients with more than 86% accuracy.
The value to our customers:
Biomarkers or multi-marker signatures that can identify patients who will respond to the treatment with a certain drug with high accuracy has very high value. In the clinical development phases this increases the chance of passing regulatory significance requirements, and such biomarkers/multi-markers may become companion or complementary diagnostics.
What we do:
In a standard multi-marker signature development project, we combine patient data (typically case-control data (responder/non-responder)) with in-depth data mining and understanding of protein pathways and networks to investigate and identify novel drug targets. The text mining includes our proprietary inBio Know™ data mining platform and for protein-protein interaction networks we apply our proprietary PPI network database, inBio Map™
We work closely with our clients in the planning of each project. Each project is tailored specifically to generate the most valuable outcome, taking available data, in-house capabilities, timelines etc. into account.
The duration of multi-marker signature projects is usually from 4 to 12 months, depending on the complexity of the project.
Close project cooperation and communication:
A key factor in the successful outcomes with our partners, is the close interaction and communication we have from planning the projects and all the way through project execution and presentation of the project deliverables. We typically have bi-weekly Webex update/planning meetings with the client and have face-to-face meetings every 2-3 months during the project. At the end of the project, we present the project deliverables and conclusions in a face-to-face meeting. All face-to-face meetings take place at our clients’ facility, unless another location is desired.
In our comprehensive project report, we deliver one or more multi-marker signatures, with evidence-based documentation for each of these. Apart from the multi-marker/signature list, the report also documents the project steps and details key project findings. Additionally, we present potential next steps in the project for discussion, if relevant.
What we do
Drug target identification
Helping clients identify genes/proteins as target candidates with remarkable results.
Helping clients uncover clinical relevant biomarkers in complex diseases enabling precise patient stratification.
Helping clients in investigating the potential of repositioning marketed drugs into other disease areas.
Helping clients decide on the correct model test platform for optimal drug development results.
Helping clients build and evolve their inhouse bioinformatic capabilities with expert counseling.